Literature DB >> 16868721

Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients.

Barbara Zdzisińska1, Adam Walter-Croneck, Anna Dmoszyńska, Martyna Kandefer-Szerszeń.   

Abstract

INTRODUCTION: Cultures of bone marrow stromal cells derived from the bone marrow of multiple myeloma (MM) patients were shown to exhibit several abnormalities compared with control cultures from healthy subjects. The aim of the study was to examine whether cultures of bone marrow adherent cells, at low passage level, exhibit differences in matrix metalloproteinases (MMPs) and cytokine production compared with cultures from normal donors.
MATERIALS AND METHODS: MMP production was evaluated by gel zymography and by ELISA in supernatants of serum-free cultures of bone marrow adherent cells derived from 20 MM patients and 23 healthy controls. Spontaneous and lipopolysaccharide (LPS)- or Newcastle disease virus (NDV)-induced cytokine release was assessed in the supernatants of the cultures by the ELISA method.
RESULTS: Both cultures produced MMP-1, -2, -3, and -9 under serum-free conditions; however, the levels of MMP-1 and MMP-2 were significantly higher in cultures derived from MM patients, while MMP-3 was significantly higher in control cultures. The level of MMP-9 was comparable in the cultures derived from MM patients and controls. All cultures produced interleukin (IL)-10 and IL-11 spontaneously, but after LPS or NDV induction the levels of IL-10, IL-11, interferon alpha, and tumor necrosis factor alpha, were significantly higher in the cultures derived from MM patients than in control cultures.
CONCLUSIONS: The results indicate that both the abnormalities in MMP production and the overproduction of cytokines (in the presence of LPS or virus, which mimic inflammatory conditions) may be involved in bone destruction and tumor spread in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868721     DOI: 10.1007/s00005-006-0033-z

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  5 in total

Review 1.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

2.  Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.

Authors:  Stephanie Markovina; Natalie S Callander; Shelby L O'Connor; Guangwu Xu; Yufang Shi; Catherine P Leith; KyungMann Kim; Parul Trivedi; Jaehyup Kim; Peiman Hematti; Shigeki Miyamoto
Journal:  Mol Cancer       Date:  2010-07-06       Impact factor: 27.401

3.  Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.

Authors:  Kodappully Sivaraman Siveen; Nurulhuda Mustafa; Feng Li; Radhamani Kannaiyan; Kwang Seok Ahn; Alan Prem Kumar; Wee-Joo Chng; Gautam Sethi
Journal:  Oncotarget       Date:  2014-02-15

Review 4.  Neuroinflammation, Bone Marrow Stem Cells, and Chronic Pain.

Authors:  Yul Huh; Ru-Rong Ji; Gang Chen
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

5.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Authors:  Barbara Zdzisińska; Agnieszka Bojarska-Junak; Anna Dmoszyńska; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.